2023
May
11,
2023
|
07:29 AM
Europe/Amsterdam
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and pre-clinical product progress / Breadth of research reinforces AskBio’s continued commitment to the development ...
Read more
March
24,
2023
|
14:59 PM
Europe/Amsterdam
Late-stage development programs with significant potential to drive long-term growth / New R&D strategy and operating model sharpening innovation focus and strengthening early development pipeline in oncology, cardiovascular, neurology & rare disease...
Read more
March
09,
2023
|
16:14 PM
Europe/Amsterdam
Research Triangle Park, N.C.– March 9, 2023 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that Gustavo Pesquin will become the company’s next Chief Executive Officer (C...
Read more
March
07,
2023
|
08:59 AM
Europe/Amsterdam
Basel, Switzerland, March 7, 2023 — A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational software...
Read more
February
27,
2023
|
15:29 PM
Europe/Amsterdam
LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapies
Read more
January
10,
2023
|
13:59 PM
Europe/Amsterdam
Strong market uptake of Nubeqa™ and Kerendia™ / Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention / High-value late-stage development portfolio / Positive study outcomes from ce...
Read more
January
09,
2023
|
13:59 PM
Europe/Amsterdam
Research Triangle Park, N.C. (January 9, 2023) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement...
Read more
January
09,
2023
|
08:45 AM
Europe/Amsterdam
-- Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO ---- New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors u...
Read more
2022
December
20,
2022
|
19:09 PM
Europe/Amsterdam
Research Triangle Park, N.C. (December 20, 2022) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therap...
Read more
March
31,
2022
|
08:30 AM
Europe/Amsterdam
Planned investments of around €2bn over next three years / Shift of resources into strategic pharmaceutical areas by investing in key production sites, manufacturing technologies and supply chain network / Bayer is transforming its pharmaceutical div...
Read more
February
04,
2022
|
14:00 PM
Europe/Amsterdam
Review of development program led to reassessment of benefit-risk ratio in all four potential indications for the investigational P2X3 receptor antagonist
Read more
2021
November
04,
2021
|
13:00 PM
Europe/Amsterdam
"Sustainable Practices Badge" seeks to encourage the adoption of more sustainable practices by Brazil’s grain growers
Read more
May
19,
2021
|
09:00 AM
Europe/Amsterdam
Varieties will allow growers to protect their yield without leaf and fruit symptoms / Combinations of resistance in Bayer’s pre-commercial pipeline could protect against ToBRFV even under high pressure conditions...
Read more
May
17,
2021
|
19:00 PM
Europe/Amsterdam
Cambridge, Mass., and Madison, Wis. May 17, 2021 – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human ind...
Read more
February
01,
2021
|
10:30 AM
Europe/Amsterdam
Berlin, Germany, February 1, 2021 - In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member o...
Read more
2020
December
21,
2020
|
13:00 PM
Europe/Amsterdam
Companies to also enter into long-term sublease agreement and service contract / Buyer planning to use facility to produce COVID-19 vaccine and other biologics
Read more
August
27,
2020
|
10:00 AM
Europe/Amsterdam
Berlin, August 27, 2020 - The Chinese National Medical Products Administration (NMPA) has approved Xofigo® (radium-223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no know...
Read more
April
21,
2020
|
14:30 PM
Europe/Amsterdam
Investigation of combination therapies including Bayer’s chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) fina...
Read more
February
10,
2020
|
08:30 AM
Europe/Amsterdam
Berlin, February 10, 2020 - Bayer and Regeneron Pharmaceuticals, Inc., today announced two planned phase III studies, PHOTON and PULSAR, evaluating extended treatment intervals with a new aflibercept 8mg formulation for intravitreal injection in adul...
Read more
January
31,
2020
|
13:00 PM
Europe/Amsterdam
"Decision of EPA corresponds to the long-standing assessments of leading international health authorities", says Liam Condon, Bayer Board Member / The Amicus brief of the U.S. Department of Justice in the Hardeman case also support Glyphosate´s safet...
Read more
2019
October
14,
2019
|
14:30 PM
Europe/Amsterdam
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for...
Read more
September
23,
2019
|
15:00 PM
Europe/Amsterdam
Precision oncology treatment Vitrakvi® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively...
Read more
September
02,
2019
|
11:00 AM
Europe/Amsterdam
Divestiture enables Bayer to focus on core OTC business
Read more
July
26,
2019
|
13:00 PM
Europe/Amsterdam
Recommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Upon approval, larotrectinib would be the first therapy in Europe w...
Read more
February
27,
2019
|
06:00 AM
Europe/Amsterdam
Berlin, February 27, 2019 - Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) for darolutamide to the U.S. Food and Drug Administration (FDA). The submission, which was initiated in December 2018, is based...
Read more
2018
November
27,
2018
|
15:30 PM
Europe/Amsterdam
The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time
Read more
October
12,
2018
|
09:00 AM
Europe/Amsterdam
Xarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antag...
Read more
August
27,
2018
|
08:30 AM
Europe/Amsterdam
Berlin, August 27, 2018 - Bayer announced today that the marketing authorization application (MAA) for larotrectinib has been submitted to the European Medicines Agency (EMA). Larotrectinib was developed to treat adult and pediatric patients with loc...
Read more
August
01,
2018
|
13:00 PM
Europe/Amsterdam
New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new ap...
Read more
July
27,
2018
|
14:45 PM
Europe/Amsterdam
Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for th...
Read more
